Andreas W. Flemmer

Andreas W. Flemmer

Auto-generated profile, based on publicly available information

Andreas W. Flemmer

Neonatologie, Dr. v. Haunersches Kinderspital, LMU Klinikum, München

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MWMatias Wagner
Matias Wagner
GBGeza Berecki
Geza Berecki
WFWalid Fazeli
Walid Fazeli
CNClaudia Nussbaum
Claudia Nussbaum
AFAndreas W. Flemmer
Andreas W. Flemmer
IBIngo Borggraefe
Ingo Borggraefe
Early-onset SCN2A developmental and epileptic encephalopathy is caused by SCN2A gain-of-function variants. Here we describe the clinical experience with intrathecally administered elsunersen, a gapmer antisense oligonucleotide targeting SCN2A, in a female preterm infant with early-onset SCN2A developmental and epileptic encephalopathy, in an expanded access program. Before elsunersen treatement, the patient was in status epilepticus for 7 weeks with a seizure frequency of 20–25 per hour. Voltage-clamp experiments confirmed impaired channel inactivation and increased persistent current consistent with a gain-of-function mechanism. Elsunersen treatment demonstrated a favorable safety profile with no severe or serious adverse events reported after 19 intrathecal administrations over 20 months. After administration in combination with sodium channel blockers, status epilepticus was interrupted intermittently and ultimately ceased after continued dosing. A >60% reduction in seizure frequency corresponding to five to seven seizures per hour was observed, which has been sustained during follow-up until the age of 22 months. These data provide preliminary insights on the safety and efficacy of elsunersen in a preterm infant. Additional investigation on the benefits of elsunersen in clinical trials is warranted.

7 February 2015 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
DSDiana Schwilling
Diana Schwilling
MVMichael Vogeser
Michael Vogeser
FKFabian Kirchhoff
Fabian Kirchhoff
FSFrauke Schwaiblmair
Frauke Schwaiblmair
ABAnne‐Laure Boulesteix
Anne‐Laure Boulesteix
AFAndreas W. Flemmer
Andreas W. Flemmer

15 April 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KFKai Förster
Kai Förster
SSSteffen Sass
Steffen Sass
Harald EhrhardtHarald Ehrhardt
Harald Ehrhardt
DMDaphne S. Mous
Daphne S. Mous
RRRobbert Rottier
Robbert Rottier
AHAnne Hilgendorff
Anne Hilgendorff

11 May 2022 in Neonatology
Verified
Journal Article
Open access
PDF file
ESEsther Schouten
Esther Schouten
JHJohanna Haupt
Johanna Haupt
JRJessily Ramirez
Jessily Ramirez
NSNick Sillett
Nick Sillett
CNChristina Nielsen
Christina Nielsen
AFAndreas Flemmer
Andreas Flemmer
Introduction: Approximately, one in ten infants is born preterm or requires hospitalization at birth. These complications at birth have long-term consequences that can extend into childhood and adulthood. Timely detection of developmental delay through surveillance could enable tailored support for these babies and their families. However, the possibilities for follow-up are limited, especially in middle- and low-income countries, and the tools to do so are either not available or too expensive. A standardized and core set of outcomes for neonates, with feasible tools for evaluation and follow-up, could result in improving quality, enhance shared decision-making, and enable global benchmarking. Methods: The International Consortium for Health Outcomes Measurement (ICHOM) convened an international working group, which was comprised of 14 health-care professionals (HCP) and 6 patient representatives in the field of neonatal care. An outcome set was developed using a three-round modified Delphi process, and it was endorsed through a patient representative-validation survey and an HCP survey. Results: A literature review revealed 1,076 articles and 26 registries which were screened for meaningful outcomes, patient-reported outcome measures, clinical measures, and case mix variables. This resulted in a neonatal set with 21 core outcomes covering three domains (physical, social, and mental functioning) and 14 tools to assess these outcomes at three timepoints. Discussion: This set can be implemented globally and it will allow comparison of outcomes across different settings and countries. The transparent consensus-driven development process which involved stakeholders and professionals from all over the world ensures global relevance.

29 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CRChristian J. Roth
Christian J. Roth
KFKai M. Förster
Kai M. Förster
AHAnne Hilgendorff
Anne Hilgendorff
BEBirgit Ertl-Wagner
Birgit Ertl-Wagner
WWWolfgang A. Wall
Wolfgang A. Wall
AFAndreas W. Flemmer
Andreas W. Flemmer
High-frequency oscillatory ventilation (HFOV) is a commonly used therapy applied to neonates requiring ventilatory support during their first weeks of life. Despite its wide application, the underlying gas exchange mechanisms promoting the success of HVOF in neonatal care are not fully understood until today. In this work, a highly resolved computational lung model, derived from Magnetic Resonance Imaging (MRI) and Infant Lung Function Testing (ILFT), is used to reveal the reason for highly efficient gas exchange during HFOV, in the preterm infant. In total we detected six mechanisms that facilitate gas exchange during HFOV: (i) turbulent vortices in large airways; (ii) asymmetric in- and expiratory flow profiles; (iii) radial mixing in main bronchi; (iv) laminar flow in higher generations of the respiratory tract; (v) pendelluft; (vi) direct ventilation of central alveoli. The illustration of six specific gas transport phenomena during HFOV in preterm infants advances general knowledge on protective ventilation in neonatal care and can support decisions on various modes of ventilatory therapy at high frequencies.

30 March 2021 in Neonatology
Verified
Journal Article
Closed access
PDF file
ASAnna-Lisa Sorg
Anna-Lisa Sorg
MKMathias Klemme
Mathias Klemme
RKRüdiger von Kries
Rüdiger von Kries
UFUrsula Felderhoff-Müser
Ursula Felderhoff-Müser
AFAndreas W. Flemmer
Andreas W. Flemmer
Mark DzietkoMark Dzietko
Mark Dzietko
Introduction: Relative risk, risk factors, clinical presentation, onset of symptoms, and age at diagnosis differ between arterial ischaemic stroke (AIS) and cerebral sinovenous thrombosis (CSVT) in neonates. Distinguishing these 2 entities in time clinically can be of eminent importance. Methods: Active surveillance for AIS and CSVT was performed in 345 German paediatric hospitals. Only cases confirmed by cerebral MRI were included in our analysis. Patients with AIS were compared to CSVT cases with regard to age at diagnosis, pattern of clinical symptoms, and risk factors. Results: Data on 144 AIS and 51 CSVT neonatal cases were collected from 2015 to 2017. The relative risk of AIS was 2.8 (95% CI 2.1; 3.9) times higher than that of CSVT. CSVT patients were more likely to be born premature (CSVT 14/48, 29.2%; AIS 19/140, 13.2%; p = 0.02) and to have signs of perinatal acidosis (e.g., umbilical artery pH ≤ 7.1 30.2% CSVT vs. 13.5% AIS p = 0.01). Generalized seizures and lethargy were more likely to occur in infants with CSVT (p < 0.0001). Age at onset of symptoms and at time of diagnoses was shifted to older ages in CSVT (p < 0.0001). Discussion/Conclusion: The risk for AIS is about 3 times higher than that for CSVT in neonates. A higher proportion of critically ill infants in CSVT and a later onset of symptoms may indicate that perinatal and postnatal risk factors are more important for CSVT than for AIS. The data underline the need for an increased awareness of CSVT in critically ill infants.